


## Analysis of Olmesartan medoxomil

(Under the Condition of United States Pharmacopeia 35-NF30)



### Conditions

**System** : GL-7400 HPLC system  
**Column** : InertSustain C18  
 (5 $\mu$ m, 150  $\times$  4.6 mm I.D.)  
**Column Cat. No.** : 5020-07345  
**Eluent** : A) CH<sub>3</sub>CN  
 B) 15 mM KH<sub>2</sub>PO<sub>4</sub> (pH3.4, H<sub>3</sub>PO<sub>4</sub>)  
 A/B = 34/66, v/v  
**Flow Rate** : 1.0 mL/min  
**Col. Temp.** : 40 °C  
**Detection** : UV 250 nm (GL-7452 PDA Detector)  
**Injection Vol.** : 10  $\mu$ L

### Analyte:

1. Olmesartan medoxomil 50 mg/L  
 2. *p*-Hydroxybenzoic acid isobutyl ester 25 mg/L

Resolution (1, 2) : 6.2 ( $\geq$  4)  
 RSD of the peak  
 area ratio of  
 1 to 2 (%) (n=6) : 0.18 ( $\leq$  0.5)